Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 13/20 | 0.56 |
| ▸ | SCN3A | Q9NY46 | 8/20 | 0.56 |
| ▸ | DPP4 | P27487 | 1/20 | 0.52 |
| ▸ | SCN1A | P35498 | 1/20 | 0.44 |
| ▸ | SCN4A | P35499 | 1/20 | 0.44 |
| ▸ | SCN7A | Q01118 | 1/20 | 0.44 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.44 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.44 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.44 |
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.44 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.44 |
| ▸ | S1PR4 | O95977 | 2/20 | 0.43 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.43 |
| ▸ | S1PR5 | Q9H228 | 2/20 | 0.43 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL135106 | 1.00 | KCNH2 (0.56) | KCNH2SCN3ADPP4SCN1ASCN4A | |
| SCHEMBL8513273 | 1.00 | KCNH2 (0.56) | KCNH2SCN3ADPP4SCN1ASCN4A | |
| SCHEMBL197791 | 1.00 | KCNH2 (0.56) | KCNH2SCN3ADPP4SCN1ASCN4A | |
| SCHEMBL197425 | 1.00 | KCNH2 (0.56) | KCNH2SCN3ADPP4SCN1ASCN4A | |
| SCHEMBL135105 | 1.00 | KCNH2 (0.56) | KCNH2SCN3ADPP4SCN1ASCN4A | |
| SCHEMBL1226045 | 1.00 | KCNH2 (0.56) | KCNH2SCN3ADPP4SCN1ASCN4A | |
| Hydrochloric Acid SCHEMBL5513962 | 0.98 | KCNH2 (0.55) | KCNH2SCN3ADPP4SCN1ASCN4A | |
| Hydrochloric Acid SCHEMBL11235696 | 0.98 | KCNH2 (0.55) | KCNH2SCN3ADPP4SCN1ASCN4A | |
| Hydrochloric Acid SCHEMBL8870650 | 0.98 | KCNH2 (0.55) | KCNH2SCN3ADPP4SCN1ASCN4A | |
| Hydrochloric Acid SCHEMBL8870646 | 0.98 | KCNH2 (0.55) | KCNH2SCN3ADPP4SCN1ASCN4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 110 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240096612-A1 | METHOD FOR MASS SPECTROMETRY OF ORGANIC SYNTHETIC COMPOUND | SHIMADZU CORPORATION (JP) | 2024-03-21 | — | — | US | claimed |
| EP-4293350-A1 | METHOD FOR MASS SPECTROMETRY OF ORGANIC SYNTHETIC COMPOUND | Shimadzu Corporation (JP) | 2023-12-20 | — | — | EP | claimed |
| WO-2022172500-A1 | METHOD FOR MASS SPECTROMETRY OF ORGANIC SYNTHETIC COMPOUND | 株式会社 島津製作所 | 2022-08-18 | — | — | WO | claimed |
| US-20200031866-A1 | PEPTIDE INHIBITORS OF SODIUM CHANNELS | SPYRYX BIOSCIENCES INC (US) | 2020-01-30 | — | — | US | claimed |
| WO-2019067887-A1 | ENAC INHIBITOR PEPTIDES AND USES THEREOF | Spyryx Biosciences, Inc. (US) | 2019-04-04 | — | — | WO | claimed |
| US-20190071468-A1 | PEPTIDE INHIBITORS OF SODIUM CHANNELS | UNIV NORTH CAROLINA CHAPEL HILL (US) | 2019-03-07 | — | — | US | claimed |
| WO-2018064499-A1 | PEPTIDE INHIBITORS OF SODIUM CHANNELS | Spyryx Biosciences, Inc. (US) | 2018-04-05 | — | — | WO | claimed |
| US-9896481-B2 | Modified mini-hepcidin peptides and methods of using thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-02-20 | — | — | US | claimed |
| US-20170327538-A1 | Peptide Inhibitors of Sodium Channels | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2017-11-16 | — | — | US | claimed |
| EP-3204029-A1 | IMPROVED PEPTIDE INHIBITORS OF SODIUM CHANNELS | The University of North Carolina at Chapel Hill (US) | 2017-08-16 | — | — | EP | claimed |
| WO-2016057795-A1 | IMPROVED PEPTIDE INHIBITORS OF SODIUM CHANNELS | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2016-04-14 | — | — | WO | claimed |
| US-20160102121-A1 | Peptide Inhibitors of Sodium Channels | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-04-14 | — | — | US | claimed |
| US-20260108618-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS | CIDARA THERAPEUTICS, INC. | 2026-04-23 | — | — | US | disclosed |
| US-12569565-B2 | Compositions and methods for the treatment of viral infections | CIDARA THERAPEUTICS, INC. (US) | 2026-03-10 | — | — | US | disclosed |
| US-20260066044-A1 | SYSTEM AND METHOD FOR PREDICTION OF UNINTENDED GENE EXPRESSION IMPACT IN A FERMENTATION PROCESS | ACCENTURE GLOBAL SOLUTIONS LTD (IE) | 2026-03-05 | — | — | US | disclosed |
| US-20250325644-A1 | ALK POLYPEPTIDES AND METHODS OF USE THEREOF | ELICIO THERAPEUTICS INC (US) | 2025-10-23 | — | — | US | disclosed |
| WO-2011073376-A1 | PYRROLIDINE OR THIAZOLIDINE CARBOXYLIC ACID DERIVATIVES, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN TREATING METABOLIC DISORDERSAS AS AGONISTS OF G- PROTEIN COUPLED RECEPTOR 43 (GPR43) | EUROSCREEN S.A. (BE) | 2011-06-23 | — | — | WO | disclosed |
| EP-1663975-A1 | NOVEL GAMMA SECRETASE INHIBITORS | SCHERING CORPORATION (US) | 2006-06-07 | — | — | EP | disclosed |
| WO-2005028440-A1 | NOVEL GAMMA SECRETASE INHIBITORS | SCHERING CORPORATION (US) | 2005-03-31 | — | — | WO | disclosed |
| WO-1993020099-A2 | CCK AND/OR GASTRIN RECEPTOR LIGANDS | FERRING B.V. (NL) | 1993-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260108618-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS | FCGR3B, FCGR1A, FCGR2A | KCNH2 3399/4885SCN3A 2819/4885DPP4 156/4885 |
| US-12569565-B2 | Compositions and methods for the treatment of viral infections | ALB, FCGR3B, FCGR1A | KCNH2 3720/4885SCN3A 2506/4885DPP4 77/4885 |
| US-20260066044-A1 | SYSTEM AND METHOD FOR PREDICTION OF UNINTENDED GENE EXPRESSION IMPACT IN A FERMENTATION PROCESS | SCLY, SPOUT1, ADH5 | KCNH2 4492/4885SCN3A 3455/4885DPP4 2237/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.